Kolkata Gynecological Oncology Trials & Translational Research Group

What Kolkata Gynecological Oncology Trials & Translational Research Group does

Kolkata Gynecological Oncology Trials and Translational Research Group (KolGOTrg) is an India-registered non-profit research consortium founded in 2018 in Kolkata, dedicated to improving quality and duration of life for women with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal) through clinical and translational research. It is the first research group from India and South Asia to become a member of the global Gynecologic Cancer InterGroup (GCIG), enabling participation in GCIG/CCRN clinical trial platforms, and operates the KolGoTrg Biobank, the first semi-automated, GCIG-approved biobank in Eastern India, integrated with hospitals, research institutes and industry partners. KolGoTrg runs an integrated stack of operating units: a Clinical Trials Design and Statistical Unit (CDSU), the Regional Ovarian Cancer Centre KolGOTrg (ROCK) for telemedicine, central MDT, trial MDT and precision-medicine MDT, a survivor empowerment group called Sarbojaya, and India's first Patient Public Involvement (PPI) toolkit modelled on Cancer Research UK and NIHR frameworks.

KolGoTrg's core research portfolio spans joint clinical trials in gynecological cancers (including the landmark pan-India ICMR-funded IPIROC trial of intermittent PARP inhibitor rucaparib in ovarian cancer), translational studies under the PROVAT series with Strand Life Sciences and MEDGENOME, biomarker assay development (academic HRD testing, Rad51 assay), nurse-led genetic counselling through the NuGenA project, screening and observational studies, and education programmes including a master's in Gynecological Oncology with Teesside University (UK). It operates across India through member institutes and collaborating hospitals and has established formal MOUs with Strand Life Sciences, MEDGENOME, Suraksha Diagnostics, I3T, the World Ovarian Cancer Coalition, and OVARCOME USA, alongside government funding from ICMR, SERB, DST-UKIERI, CSIR HCP 40, and philanthropic support from Jivdaya Foundation USA.

The organisation is led by Dr. Asima Mukhopadhyay as Director of KolGOTrg and ROCK. It does not sell products or services, does not publicly disclose pricing, and provides access to clinical-trial medications free of charge to eligible patients; its operations are funded primarily through competitive government grants, industry-supported translational collaborations, and philanthropic donations solicited through its website. With a registered office at CNCI Kolkata and a research office in New Town, Kolkata, and a headcount of 1-10 employees, KolGOTrg functions as a focused, grant-funded academic clinical-translational platform within the Indian gynecological oncology ecosystem.

Name

Kolkata Gynecological Oncology Trials & Translational Research Group

Legal name

Kolkata Gynecological Oncology Trials & Translational Research Group

Website

https://kolgotrg.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

KolGOTrg is a Kolkata-based non-profit research consortium founded in 2018 that conducts clinical trials and translational studies in gynecological cancers for women in India, operating the first GCIG-approved biobank in Eastern India and serving patients, survivors, and academic collaborators.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAGACAG

Clinical Trial Monitoring Support (On-site/Remote)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

SECONDARYHLAJAOAM

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAGALAM

KOL Engagement & Medical Education (Advisory Boards/CME Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Pharmacovigilance & Medical Affairs Services

Keywords

• Clinical trial research
• Gynecological oncology research
• Translational cancer research
• Cancer biobanking services
• Patient advocacy programs

Headquarters

HQ city

Kolkata, West Bengal

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Core offering

KolGOTrg is a non-profit clinical and translational research consortium that designs and runs clinical trials, translational studies, and survivorship programs for women with gynecological cancers in India. It operates the KolGoTrg Biobank (the first semi-automated bio-repository in Eastern India) and integrates hospitals, research institutes, and industry partners to deliver research infrastructure and free patient access to costly targeted therapies such as PARP inhibitors.

Product overview

KolGoTrg is a research organization offering a portfolio of clinical and translational research products and services focused on gynecological cancers. The core offerings include: (1) KolGoTrg Biobank - Eastern India's first biobank integrated with hospitals and research institutes; (2) CDSU - Clinical Trials Design and Statistical Unit providing methodological and statistical expertise; (3) ROCK - Regional Ovarian Cancer Centre providing telemedicine, MDT consultations, and precision medicine; (4) Sarbojaya - survivor empowerment group; (5) Patient Public Involvement Toolkit - first PPI model in India; (6) Clinical trials and translational studies including IPIROC, NuGenA, PROVAT studies; (7) Education and training programs. The organization connects these components through its research infrastructure to improve quality and duration of life for women with gynecological cancers in India.

Differentiator

Problem solved

Functional benefit

Brands

• CDSU (Clinical Trials Design and Statistical Unit): Dedicated unit advancing high-quality research through expert support in clinical trial methodology and statistical analysis.
• ROCK (Regional Ovarian Cancer Centre KolGOTrg)
• Sarbojaya
• KolGoTrg Biobank

Products and services

• KolGoTrg Biobank A semi-automated bio-repository and the first biobank in Eastern India, integrated with hospitals, research institutes and industry partners to support multiple translational studies with targeted deliverables including biomarker and HRD assays.
• CDSU (Clinical Trials Design and Statistical Unit) A dedicated unit providing expert support in clinical trial methodology and statistical analysis to enhance the design, implementation, and interpretation of clinical research studies.
• ROCK (Regional Ovarian Cancer Centre KolGOTrg) A women's cancer centre providing telemedicine, health informatics, central MDT consultations, trial MDT, precision medicine MDT, survivor support, prevention programs, and education modules for ovarian cancer care.
• IPIROC Clinical Trial An ICMR-funded clinical trial in ovarian cancer providing free access to the PARP inhibitor rucaparib, designed to optimize dosing and reduce side effects and cost for eligible patients across India.
• Translational Research Studies Translational research studies including the PROVAT series studies, the NuGenA nurse-led genetic counselling project, and various biomarker assay development projects (HRD and PARP assays) for patient selection.
• Education and Training Programs Educational activities including lectures, workshops, and master's programs in Gynecological Oncology delivered in collaboration with Teesside University, UK, with CRS modules for healthcare providers.

Quantifiable outcome

• NuGenA nurse-led genetic counselling project won Charter Champion award from the World Ovarian Cancer Coalition

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Nine partnerships are on record, tiered minor and core.

• OVARCOME USAminorStrategic or Co-development Partner · 7 January 2021MOU signed on 7th January 2021 for collaboration on projects in ovarian cancer and advocacy. OVARCOME will part fund the pilot project NuGenA on nurse-led genetic counselling and awareness.
• I3T (International Institute for Innovation and Technology)minorStrategic or Co-development Partner · 17 January 2020Formal MOU signed on 17th January 2020 to collaborate on areas of cancer biology and public health projects including education and training courses for healthcare providers in cancer.
• MEDGENOMEcoreStrategic or Co-development Partner · 16 October 2019Supported inaugural series meeting in April 2018. Formal MOU signed on 16th October 2019 to support biobanking and PROVAT translational group of studies. Academic partners in academia-industry collaboration for grant application on Immune Oncology and genetics (Wellcome Trust DBT IA fellowship application).
• Strand Life SciencescoreStrategic or Co-development Partner · 7 January 2018Supported inaugural meeting on 7th January 2018. Formal MOU signed to support genetic counselling training programme and as external partner for DST-UKIERI (PROVAT 1 project) including collaboration with DFCI, Harvard for PROVAT-6 study.
• DST UKIERIcoreStrategic or Co-development PartnerSupported 1st Translational Research Day on 31st January 2018 at Tata Medical Centre, Kolkata and 1st annual meeting in March 2019. Many KolGoTrg projects funded through in-kind contribution from DST UKIERI grant as parent project, including collaborative efforts with UCL CTC (CRUK) which laid foundation for GCIG collaboration.
• GCIG (Gynecologic Cancer InterGroup)coreStrategic or Co-development PartnerKolGoTrg is proud to be the first ever research group from India to become a member group of GCIG and participate in GCIG/CCRN clinical trials. Presented own studies at the platform for the 1st time from India in the 2020 virtual spring meeting held at Chicago, working towards becoming a full member.
• World Ovarian Cancer Coalition (WOCC)coreStrategic or Co-development PartnerKolGoTrg is a charter champion and featured in WOCC presentations including IGCS presidential plenary session September 2020. WOCC is collaborator for NuGenA and participant in WOCC Every Woman study from India.
• Suraksha Diagnostics LtdcoreStrategic or Co-development PartnerProvided space for ROCK (Regional Ovarian Cancer Centre KolGOTrg) and laboratory facilities for biobanking and development of next generation biomarker assays like academic HRD and PARP assay for patient selection, through unique R&D collaboration with KolGOTrg. Directors Dr. Somnath Chatterjee and Ritu Mittal facilitated study setup.
• BDR PharmaceuticalsminorOthersSupporting 1st phase of IPIROC study and providing Pan-India coordination for availability of PARP inhibitor rucaparib.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Others

• Indian Council of Medical Research (ICMR): Primary government funding body for KolGOTrg's IPIROC trial and key grant provider. Comparable as a research sponsor and coordinator of multi-site cancer studies in India, though operating at much larger scale.
• Suraksha Diagnostics Ltd: Indian diagnostic chain providing lab facilities and biobanking infrastructure to KolGOTrg via R&D collaboration. Functions as a regional strategic partner enabling biomarker and biobank operations, comparable as enabling infrastructure.
• National Cancer Grid (NCG) India: Network of cancer centers in India enabling collaborative multi-site oncology research and clinical trials. An adjacent enabling/ecosystem organization similar in collaborative role to KolGOTrg within the Indian oncology research landscape.

Direct peers

• NRG Oncology: US National Cancer Institute-sponsored clinical trials cooperative group running large-scale multi-site oncology trials including gynecological cancers. Most directly comparable to KolGOTrg as a cooperative-style trial sponsor/coordinator within a global oncology trials ecosystem.
• GOG Foundation / GOG Partners: Gynecologic Oncology Group successor organization dedicated to designing and conducting clinical trials in gynecologic malignancies. Directly comparable to KolGOTrg's mission of running gyn-cancer clinical trials and translational research with cooperative-group infrastructure.
• Tata Memorial Centre (TMC): India's premier cancer treatment, research and education institution that hosts the inaugural translational research day for KolGOTrg and partners on multiple oncology projects. Acts as a leading Indian cancer research/clinical trials institution analogous in mission.
• KGOG (Korean Gynecologic Oncology Group): Korean cooperative group running gynecologic cancer trials; GCIG member with similar cooperative-group operating model and translational research focus as KolGOTrg in Asia.
• ANZGOG (Australia New Zealand Gynaecological Oncology Group): GCIG-affiliated cooperative group running gynecological cancer clinical trials in Australia and New Zealand. Closely analogous small-cooperative model focused on gyn cancer, participating in international GCIG portfolio trials.
• AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) Austria/Germany: German/Austrian working group on gynecological oncology running gynecological cancer trials and translational research under GCIG. Comparable cooperative-group structure running multi-site gyn-onc trials with academic and industry sponsorship.
• European Network of Gynaecological Oncological Trial Groups (ENGOT): Network of European national gynecological cancer trial groups coordinating large multinational Phase II/III trials. Mirrors KolGOTrg's role as India/South Asia's regional gyn-cancer trial coordinator and GCIG member.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kolkata-gynecological-oncology-trials-translational-research-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kolkata Gynecological Oncology Trials & Translational Research Group